AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently amended) A compound of general formula 1,



General Formula 1

wherein:

Py represents pyridin-4-yl mono-substituted in position 2 with $-NR^2R^3$; pyridin-4-yl disubstituted in position 2 with $-NR^2R^3$ and in position 6 with lower alkyl or arylalkyl; unsubstituted quinolin-4-yl; quinolin-4-yl mono-substituted in position 2 with lower alkyl; quinolin-4-yl di-substituted in position 2 with lower alkyl and in position 6, 7, or 8 with halogen, lower alkyl, or arylalkyl; 2-hydroxymethyl-quinolin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; or 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl;

X represents aryl; aryl-O-; arylalkyl-; lower alkyl-SO_2NR^2-; aryl-SO_2NR^2-; arylalkyl-SO_2NR^2-; lower alkyl-$CONR^2$-; aryl-$CONR^2$-; arylalkyl-$CONR^2$-; lower alkyl-NR^3CONR^2-; aryl-NR^3CONR^2-; arylalkyl-NR^3CONR^2-; aryl-CO-; arylalkyl-CO-; lower alkyl-NR^2CO-;aryl-NR^2CO-; or arylalkyl-NR^2CO-; ~~or X and Z represent together with the carbon atom to which they are attached an exocyclic double bond which bears an aryl substituent.~~

Y represents $-C(R^4)(R^5)(CH_2)_m-$ or $-(CH_2)_mC(R^4)(R^5)-$;

Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen, hydroxyl, carboxyl, aryl-$CONR^2-$, lower alkyl-NR^2CO-, aryl-NR^2CO- or arylalkyl-NR^2CO-;

n represents the ~~numbers~~ number 0 or 1;

m represents the ~~numbers~~ number 1 or 2;

R^1 represents hydrogen or lower alkyl;

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R^2 and R^3 are attached to the same nitrogen atom, R^2 and R^3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring;

R^4 represents hydrogen, lower alkyl, aryl, arylalkyl, or forms together with R^5 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms; and

R^5 represents hydrogen, methyl, or forms together with R^4 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms[[;]].

[[and]] or an optically pure ~~enantiomers or diastereomers~~ enantiomer or diastereomer, ~~mixtures~~ a mixture of enantiomers or diastereomers, a diastereomeric ~~racemates~~ racemate, and a ~~mixtures~~ mixture of diastereomeric racemates; ~~as well as their~~ or a pharmaceutically acceptable ~~salts, solvent complexes, and morphological forms~~ salt, of said compound.

2. (Currently amended) A compound of general formula 2,



General Formula 2

wherein:

Py represents 2-(benzyl-methyl-amino)-pyridin-4-yl; 2-(benzyl-methyl-amino)-6-methyl-pyridin-4-yl; 2-(benzylamino)-pyridin-4-yl; 2-benzylamino-6-methyl-pyridin-4-yl; 2-(dimethylamino)-pyridin-4-yl; 2-(dimethylamino)-6-methyl-pyridin-4-yl; 2-(methylamino)-pyridin-4-yl; 2-(methylamino)-6-methyl-pyridin-4-yl; 2-aminopyridin-4-yl; 2-amino-6-methyl-pyridin-4-yl; 2-(pyrrolidin-1-yl)-pyridin-4-yl; quinol-4-yl; 2-methylquinol-4-yl; 2-cyclopropylquinol-4-yl; 8-benzyl-2-methyl-quinol-4-yl; [1,8]naphthyridin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; or 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl;

X represents aryl; aryl-O-; arylalkyl-; lower alkyl-SO_2NR^2-; aryl-SO_2NR^2-; arylalkyl-SO_2NR^2-; lower alkyl-$CONR^2$-; aryl-$CONR^2$-; arylalkyl-$CONR^2$-; lower alkyl-NR^3CONR^2-; aryl-NR^3CONR^2-; arylalkyl-NR^3CONR^2-; aryl-CO-; arylalkyl-CO-; lower alkyl-NR^2CO-;aryl-NR^2CO-; or arylalkyl-NR^2CO-;

Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen or hydroxyl;

n represents the ~~numbers~~ number 0 or 1;

m represents the ~~numbers~~ number 1 or 2;

R^1 represents hydrogen or lower alkyl; and

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl,

or a pharmaceutically acceptable salt of said compound.

3. (Currently amended) A compound of general formula 3,



General formula 3

wherein: ~~n, Y and Py have the meaning given in general formula 1 of claim 1~~

Py represents pyridin-4-yl mono-substituted in position 2 with $-NR^2R^3$; pyridin-4-yl disubstituted in position 2 with $-NR^2R^3$ and in position 6 with lower alkyl or arylalkyl; unsubstituted quinolin-4-yl; quinolin-4-yl mono-substituted in position 2 with lower alkyl; quinolin-4-yl di-substituted in position 2 with lower alkyl and in position 6, 7, or 8 with halogen, lower alkyl, or arylalkyl; 2-hydroxymethyl-quinolin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl;

Y represents $-C(R^4)(R^5)(CH_2)_m-$ or $-(CH_2)_mC(R^4)(R^5)-$;

n represents the number 0 or 1;

m represents the number 1 or 2;

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R^2 and R^3 are attached to the same nitrogen atom, R^2 and R^3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring;

R^4 represents hydrogen, lower alkyl, aryl, arylalkyl, or forms together with R^5 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms; and

R^5 represents hydrogen, methyl, or forms together with R^4 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms,

or a pharmaceutically acceptable salt of said compound.

4. (Currently amended) A compound of general formula 4,



General formula 4

wherein; ~~n and Py has the meaning given in general formula 2 of claim 2~~

Py represents 2-(benzyl-methyl-amino)-pyridin-4-yl; 2-(benzyl-methyl-amino)-6-methyl-pyridin-4-yl; 2-(benzylamino)-pyridin-4-yl; 2-benzylamino-6-methyl-pyridin-4-yl; 2-(dimethylamino)-pyridin-4-yl; 2-(dimethylamino)-6-methyl-pyridin-4-yl; 2-(methylamino)-pyridin-4-yl; 2-(methylamino)-6-methyl-pyridin-4-yl; 2-aminopyridin-4-yl; 2-amino-6-methyl-pyridin-4-yl; 2-(pyrrolidin-1-yl)-pyridin-4-yl; quinol-4-yl; 2-methylquinol-4-yl; 2-cyclopropylquinol-4-yl; 8-benzyl-2-methyl-quinol-4-yl; [1,8]naphthyridin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-

methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; or 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; and

n represents the number 0 or 1,

or a pharmaceutically acceptable salt of said compound.

5. (Currently amended) A compound of general formula 5,



General formula 5

wherein: ~~R^2, Y and Py have the meaning given in general formula 1 of claim 1~~

Py represents pyridin-4-yl mono-substituted in position 2 with $-NR^2R^3$; pyridin-4-yl disubstituted in position 2 with $-NR^2R^3$ and in position 6 with lower alkyl or arylalkyl; unsubstituted quinolin-4-yl; quinolin-4-yl mono-substituted in position 2 with lower alkyl; quinolin-4-yl di-substituted in position 2 with lower alkyl and in position 6, 7, or 8 with halogen, lower alkyl, or arylalkyl; 2-hydroxymethyl-quinolin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl;

Y represents $-C(R^4)(R^5)(CH_2)_m-$ or $-(CH_2)_mC(R^4)(R^5)-$;

m represents the number 1 or 2;

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R^2 and R^3 are attached to the same nitrogen atom, R^2 and R^3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring;

R^4 represents hydrogen, lower alkyl, aryl, arylalkyl, or forms together with R^5 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms; and

R^5 represents hydrogen, methyl, or forms together with R^4 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms,

or a pharmaceutically acceptable salt of said compound.

6. (Currently amended) A compound of general formula 6,



General formula 6

wherein: ~~R^2 and Py have the meaning given in general formula 2 of claim 2~~

Py represents 2-(benzyl-methyl-amino)-pyridin-4-yl; 2-(benzyl-methyl-amino)-6-methyl-pyridin-4-yl; 2-(benzylamino)-pyridin-4-yl; 2-benzylamino-6-methyl-pyridin-4-yl; 2-(dimethylamino)-pyridin-4-yl; 2-(dimethylamino)-6-methyl-pyridin-4-yl; 2-(methylamino)-pyridin-4-yl; 2-(methylamino)-6-methyl-pyridin-4-yl; 2-aminopyridin-4-yl; 2-amino-6-methyl-pyridin-4-yl; 2-(pyrrolidin-1-yl)-pyridin-4-yl; quinol-4-yl; 2-methylquinol-4-yl; 2-cyclopropylquinol-4-yl; 8-benzyl-2-methyl-quinol-4-yl; [1,8]naphthyridin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-

methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; or 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; and

R^2 represents hydrogen, lower alkyl, or arylalkyl,

or a pharmaceutically acceptable salt of said compound.

7. (Currently amended) A compound of general formula 7,



General formula 7

wherein: ~~R^2, Y and Py have the meaning given in general formula 1 of claim 1~~

Py represents pyridin-4-yl mono-substituted in position 2 with $-NR^2R^3$; pyridin-4-yl disubstituted in position 2 with $-NR^2R^3$ and in position 6 with lower alkyl or arylalkyl; unsubstituted quinolin-4-yl; quinolin-4-yl mono-substituted in position 2 with lower alkyl; quinolin-4-yl di-substituted in position 2 with lower alkyl and in position 6, 7, or 8 with halogen, lower alkyl, or arylalkyl; 2-hydroxymethyl-quinolin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; or 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl;

Y represents $-C(R^4)(R^5)(CH_2)_m-$ or $-(CH_2)_mC(R^4)(R^5)-$;

m represents the number 1 or 2;

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R^2 and R^3 are attached to the same nitrogen atom, R^2 and R^3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring;

R^4 represents hydrogen, lower alkyl, aryl, arylalkyl, or forms together with R^5 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms; and

R^5 represents hydrogen, methyl, or forms together with R^4 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms,

or a pharmaceutically acceptable salt of said compound.

8. (Currently amended) A compound of general formula 8,



General formula 8

wherein: ~~R^2, Y and Py have the meaning given in general formula 1 of claim 1~~

Py represents pyridin-4-yl mono-substituted in position 2 with $-NR^2R^3$; pyridin-4-yl disubstituted in position 2 with $-NR^2R^3$ and in position 6 with lower alkyl or arylalkyl; unsubstituted quinolin-4-yl; quinolin-4-yl mono-substituted in position 2 with lower alkyl; quinolin-4-yl di-substituted in position 2 with lower alkyl and in position 6, 7, or 8 with halogen, lower alkyl, or arylalkyl; 2-hydroxymethyl-quinolin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; or 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl;

Y represents $-C(R^4)(R^5)(CH_2)_m-$ or $-(CH_2)_mC(R^4)(R^5)-$;

m represents the number 1 or 2;

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R^2 and R^3 are attached to the same nitrogen atom, R^2 and R^3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring;

R^4 represents hydrogen, lower alkyl, aryl, arylalkyl, or forms together with R^5 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms; and

R^5 represents hydrogen, methyl, or forms together with R^4 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms,

or a pharmaceutically acceptable salt of said compound.

9. (Currently amended) A compound of general formula 9,



General formula 9

wherein: ~~R^2 and Py have the meaning given in general formula 2 of claim 2~~

Py represents 2-(benzyl-methyl-amino)-pyridin-4-yl; 2-(benzyl-methyl-amino)-6-methyl-pyridin-4-yl; 2-(benzylamino)-pyridin-4-yl; 2-benzylamino-6-methyl-pyridin-4-yl; 2-(dimethylamino)-pyridin-4-yl; 2-(dimethylamino)-6-methyl-pyridin-4-yl; 2-(methylamino)-pyridin-4-yl; 2-(methylamino)-6-methyl-pyridin-4-yl; 2-aminopyridin-4-yl; 2-amino-6-methyl-pyridin-4-yl; 2-(pyrrolidin-1-yl)-pyridin-4-yl; quinol-4-yl; 2-

methylquinol-4-yl; 2-cyclopropylquinol-4-yl; 8-benzyl-2-methyl-quinol-4-yl; [1,8]naphthyridin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; or 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; and

R^2 represents hydrogen, lower alkyl, or arylalkyl,

or a pharmaceutically acceptable salt of said compound.

10. (Currently amended) A compound of general formula 10,



General formula 10

wherein: ~~X, Z and Py have the meaning given in general formula 1 of claim 1~~

Py represents pyridin-4-yl mono-substituted in position 2 with $-NR^2R^3$; pyridin-4-yl disubstituted in position 2 with $-NR^2R^3$ and in position 6 with lower alkyl or arylalkyl; unsubstituted quinolin-4-yl; quinolin-4-yl mono-substituted in position 2 with lower alkyl; quinolin-4-yl di-substituted in position 2 with lower alkyl and in position 6, 7, or 8 with halogen, lower alkyl, or arylalkyl; 2-hydroxymethyl-quinolin-4-yl; 7-methyl-[1,8]naphthyridin-4-yl; 5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-benzyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 8-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-4-yl; 2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; 1-methyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl; or 1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl;

X represents aryl; aryl-O-; arylalkyl-; lower alkyl-SO_2NR^2-; aryl-SO_2NR^2-; arylalkyl-SO_2NR^2-; lower alkyl-$CONR^2$-; aryl-$CONR^2$-; arylalkyl-$CONR^2$-; lower alkyl-

NR^3CONR^2-; aryl-NR^3CONR^2-; arylalkyl-NR^3CONR^2-; aryl-CO-; arylalkyl-CO-; lower alkyl-NR^2CO-;aryl-NR^2CO-; or arylalkyl-NR^2CO-;

Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen, hydroxyl, carboxyl, aryl-$CONR^2$-, lower alkyl-NR^2CO-, aryl-NR^2CO- or arylalkyl-NR^2CO-; and

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R^2 and R^3 are attached to the same nitrogen atom, R^2 and R^3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring,

or a pharmaceutically acceptable salt of said compound.

11. (Currently amended) A compound of general formula 11,



General formula 11

wherein:

R^6 is hydrogen, lower alkyl, or arylalkyl; ~~and n, X, Y, and Z have the meaning given in general formula 1 of claim 1~~

X represents aryl; aryl-O-; arylalkyl-; lower alkyl-SO_2NR^2-; aryl-SO_2NR^2-; arylalkyl-SO_2NR^2-; lower alkyl-$CONR^2$-; aryl-$CONR^2$-; arylalkyl-$CONR^2$-; lower alkyl-NR^3CONR^2-; aryl-NR^3CONR^2-; arylalkyl-NR^3CONR^2-; aryl-CO-; arylalkyl-CO-; lower alkyl-NR^2CO-;aryl-NR^2CO-; or arylalkyl-NR^2CO-;

Y represents $-C(R^4)(R^5)(CH_2)_m-$ or $-(CH_2)_mC(R^4)(R^5)-$;

Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen, hydroxyl, carboxyl, aryl-$CONR^2$-, lower alkyl-NR^2CO-, aryl-NR^2CO- or arylalkyl-NR^2CO-;

n represents the number 0 or 1;

m represents the number 1 or 2;

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R^2 and R^3 are attached to the same nitrogen atom, R^2 and R^3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring;

R^4 represents hydrogen, lower alkyl, aryl, arylalkyl, or forms together with R^5 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms; and

R^5 represents hydrogen, methyl, or forms together with R^4 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms,

or a pharmaceutically acceptable salt of said compound.

12. (Currently amended) A compound of general formula 12,



General formula 12

wherein: ~~R^6 has the meaning given in general formula 11 of claim 11; and n, X and Z have the meaning given in general formula 2 of claim 2~~

R^6 represents hydrogen, lower alkyl, or arylalkyl;

X represents aryl; aryl-O-; arylalkyl-; lower alkyl-SO_2NR^2-; aryl-SO_2NR^2-; arylalkyl-SO_2NR^2-; lower alkyl-$CONR^2$-; aryl-$CONR^2$-; arylalkyl-$CONR^2$-; lower alkyl-NR^3CONR^2-; aryl-NR^3CONR^2-; arylalkyl-NR^3CONR^2-; aryl-CO-; arylalkyl-CO-; lower alkyl-NR^2CO-;aryl-NR^2CO-; or arylalkyl-NR^2CO-;

Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen or hydroxyl;

n represents the number 0 or 1; and

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl,

or a pharmaceutically acceptable salt of said compound.

13. (Currently amended) A compound of general formula 13,



General formula 13

wherein: ~~R^6 has the meaning given in general formula 11 of claim 11; and n, R^2, R^3, X, Y, and Z have the meaning given in general formula 1 of claim 1~~

R^6 represents hydrogen, lower alkyl, or arylalkyl;

X represents aryl; aryl-O-; arylalkyl-; lower alkyl-SO_2NR^2-; aryl-SO_2NR^2-; arylalkyl-SO_2NR^2-; lower alkyl-$CONR^2$-; aryl-$CONR^2$-; arylalkyl-$CONR^2$-; lower alkyl-NR^3CONR^2-; aryl-NR^3CONR^2-; arylalkyl-NR^3CONR^2-; aryl-CO-; arylalkyl-CO-; lower alkyl-NR^2CO-;aryl-NR^2CO-; or arylalkyl-NR^2CO-;

Y represents $-C(R^4)(R^5)(CH_2)_m-$ or $-(CH_2)_mC(R^4)(R^5)-$;

Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen, hydroxyl, carboxyl, aryl-$CONR^2$-, lower alkyl-NR^2CO-, aryl-NR^2CO- or arylalkyl-NR^2CO-;

n represents the number 0 or 1;

m represents the number 1 or 2;

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R^2 and R^3 are attached to the same nitrogen atom, R^2 and R^3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring;

R^4 represents hydrogen, lower alkyl, aryl, arylalkyl, or forms together with R^5 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms; and

R^5 represents hydrogen, methyl, or forms together with R^4 a 3-, 4-, 5-, or 6-membered saturated carbocyclic ring including the carbon atom to which R^4 and R^5 are attached as ring atoms,

or a pharmaceutically acceptable salt of said compound.

14. (Currently amended) A compound of general formula 14,



General formula 14

wherein: ~~R^6 has the meaning given in general formula 11 of claim 11; and n, R^2, R^3, X and Z have the meaning given in general formula 1 of claim 1~~

R^6 represents hydrogen, lower alkyl, or arylalkyl;

X represents aryl; aryl-O-; arylalkyl-; lower alkyl-SO_2NR^2-; aryl-SO_2NR^2-; arylalkyl-SO_2NR^2-; lower alkyl-$CONR^2$-; aryl-$CONR^2$-; arylalkyl-$CONR^2$-; lower alkyl-NR^3CONR^2-; aryl-NR^3CONR^2-; arylalkyl-NR^3CONR^2-; aryl-CO-; arylalkyl-CO-; lower alkyl-NR^2CO-;aryl-NR^2CO-; or arylalkyl-NR^2CO-;

Z represents hydrogen; in case X represents aryl or arylalkyl, Z represents hydrogen, hydroxyl, carboxyl, aryl-$CONR^2$-, lower alkyl-NR^2CO-, aryl-NR^2CO- or arylalkyl-NR^2CO-;

n represents the number 0 or 1; and

R^2 and R^3 represent independently hydrogen, lower alkyl, or arylalkyl; in case R^2 and R^3 are attached to the same nitrogen atom, R^2 and R^3 together form with the nitrogen to which they are attached, a piperidine, pyrrolidine or morpholine ring,

or a pharmaceutically acceptable salt of said compound.

15. (Currently amended) A compound of general formula 15,



General formula 15

wherein R^6 ~~has the meaning given in general formula 11 of claim 11~~ represents hydrogen, lower alkyl, or arylalkyl,

or a pharmaceutically acceptable salt of said compound.

16. (Currently amended) A compound of general formula 16,



General formula 16

wherein R^6 ~~has the meaning given in general formula 11 of claim 11~~ represents hydrogen, lower alkyl, or arylalkyl,

or a pharmaceutically acceptable salt of said compound.

17. (Currently amended) A compound of general formula 17,



General formula 17

wherein R^6 ~~has the meaning given in general formula 11 of claim 11;~~ and R^2 ~~has the meaning given in general formula 1 of claim 1~~ represent independently hydrogen, lower alkyl, or arylalkyl,

or a pharmaceutically acceptable salt of said compound.

18. (Currently amended) A compound of general formula 18,



General formula 18

wherein R^6 ~~has the meaning given in general formula 11 of claim 11;~~ and R^2 ~~has the meaning given in general formula 1 of claim 1~~ represent independently hydrogen, lower alkyl, or arylalkyl,

or a pharmaceutically acceptable salt of said compound.

19. (Currently amended) A compound of general formula 19,



General formula 19

wherein R^6 ~~has the meaning given in general formula 11 of claim 11;~~ and R^2 ~~has the meaning given in general formula 1 of claim 1~~ represent independently hydrogen, lower alkyl, or arylalkyl,

or a pharmaceutically acceptable salt of said compound.

20. (Currently amended) A compound of general formula 20,



General formula 20

wherein R^6 ~~has the meaning given in general formula 11 of claim 11;~~ and R^2 ~~has the meaning given in general formula 1 of claim 1~~ represent independently hydrogen, lower alkyl, or arylalkyl,

or a pharmaceutically acceptable salt of said compound.

21. (Currently amended) The compound according to claim 1 that is selected from the group consisting of

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-trifluoromethyl-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

Thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

3-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

3,N-Dimethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

2-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

2,N-Dimethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4,N-Dimethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

2-Fluoro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

2-Fluoro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

3-Fluoro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Fluoro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Cyano-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3-Methoxy-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

3-Methoxy-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Methoxy-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Methoxy-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Methoxy-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

3-Chloro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

3-Chloro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Chloro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Chloro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

2-Chloro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

Biphenyl-4-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-propyl-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-propyl-benzenesulfonamide;

Naphthalene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

Naphthalene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

Naphthalene-2-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

Naphthalene-1-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

Naphthalene-1-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

Naphthalene-1-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

Quinoline-8-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

Quinoline-8-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

4-tert-Butyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-tert-Butyl-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-trifluoromethyl-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-trifluoromethyl-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-trifluoromethyl-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-2-trifluoromethyl-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-2-trifluoromethyl-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-3-trifluoromethyl-benzenesulfonamide;

3,4-Dichloro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3,4-Dichloro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-pentyl-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-pentyl-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-pentyl-benzenesulfonamide;

4-Butoxy-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Butoxy-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4,5-Dichloro-thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

4,5-Dichloro-thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

4,5-Dichloro-thiophene-2-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

4-(3-Chloro-2-cyano-phenoxy)-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-(3-Chloro-2-cyano-phenoxy)-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-(3-Chloro-2-cyano-phenoxy)-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-[4-Methyl-5-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-ylsulfamoyl)-thiazol-2-yl]-acetamide;

3-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

3-Bromo-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-2-trifluoromethoxy-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-trifluoromethoxy-benzenesulfonamide;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-trifluoromethoxy-benzenesulfonamide;

N-Methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-4-trifluoromethoxy-benzenesulfonamide;

5-Dimethylamino-naphthalene-1-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

5-Dimethylamino-naphthalene-1-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

5-Dimethylamino-naphthalene-1-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

5-Chloro-3-methyl-benzo[b]thiophene-2-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

4-Bromo-2-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Bromo-2-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-2-ethyl-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-[5-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-ylsulfamoyl)-thiophen-2-ylmethyl]-benzamide;

N-[5-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-ylsulfamoyl)-thiophen-2-ylmethyl]-benzamide;

N-{5-[Methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-sulfamoyl]-thiophen-2-ylmethyl}-benzamide;

4-Benzenesulfonyl-thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

4-Benzenesulfonyl-thiophene-2-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

4-Benzenesulfonyl-thiophene-2-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

2-(2,2,2-Trifluoro-acetyl)-1,2,3,4-tetrahydro-isoquinoline-7-sulfonic acid methyl-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-amide;

2-Phenyl-ethanesulfonic acid (1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

4-Chloro-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

1-{2-[4-(3-Biphenyl-2-yl-ureido)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;

1-{2-[3-(3-Biphenyl-2-yl-ureido)-pyrrolidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;

1-(2-{4-[3-(2-Isopropyl-phenyl)-ureido]-piperidin-1-yl}-ethyl)-3-(2-methyl-quinolin-4-yl)-urea;

1-(2-{3-[3-(2-Isopropyl-phenyl)-ureido]-pyrrolidin-1-yl}-ethyl)-3-(2-methyl-quinolin-4-yl)-urea;

1-(2-Methyl-quinolin-4-yl)-3-(2-{3-[3-(2-phenoxy-phenyl)-ureido]-pyrrolidin-1-yl}-ethyl)-urea;

N-(1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-naphthalen-1-yl-acetamide;

2-(4-Bromo-phenyl)-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-acetamide;

4-Benzoyl-N-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzamide;

1-(2-Methyl-quinolin-4-yl)-3-[2-(4-phenyl-piperidin-1-yl)-ethyl]-urea;

1-(2-Methyl-quinolin-4-yl)-3-[2-(4-o-tolyl-piperidin-1-yl)-ethyl]-urea;

1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[2-(4-Hydroxy-4-phenyl-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea; and

1-[2-(Benzyl-methyl-amino)-pyridin-4-yl]-3-[2-(4-benzyl-piperidin-1-yl)-ethyl]-urea,

or a pharmaceutically acceptable salt of said compound.

22. (Currently amended) The compound according to claim 1 that is selected from the group consisting of

4-Bromo-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Bromo-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-N-propyl-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-N-propyl-benzenesulfonamide;

4-Bromo-N-isobutyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Bromo-N-isobutyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-butyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Bromo-N-butyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-Benzyl-4-bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Benzyl-4-bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-N-phenethyl-benzenesulfonamide;

4-Bromo-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-N-phenethyl-benzenesulfonamide;

4-Bromo-N-methyl-N-((R)-1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-ethyl-N-((R)-1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-ethyl-N-((S)-1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

4-Bromo-N-methyl-N-((S)-1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-pyrrolidin-3-yl)-benzenesulfonamide;

N-Ethyl-3-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Ethyl-4-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Ethyl-2-methyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3-Chloro-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

2-Chloro-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

4-Chloro-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Ethyl-4-fluoro-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Ethyl-4-methoxy-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3,4-Dichloro-N-ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

N-Ethyl-N-(1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-trifluoromethyl-benzenesulfonamide;

1-(2-Methyl-quinolin-4-yl)-3-{2-[4-(3-phenethyl-ureido)-piperidin-1-yl]-ethyl}-urea;

1-[(S)-1-(4-Benzyl-piperidin-1-ylmethyl)-2-methyl-propyl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[(S)-1-Benzyl-2-(4-benzyl-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[(S)-1-(4-Benzyl-piperidin-1-ylmethyl)-3-methyl-butyl]-3-(2-methyl-quinolin-4-yl)-urea;

1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-cyclopropyl-quinolin-4-yl)-urea;

~~1-{2-[4-(3-Methyl-benzylidene)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;~~

~~1-{2-[4-(2-Methyl-benzylidene)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;~~

~~1-{2-[4-(4-Methoxy-benzylidene)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;~~

~~1-{2-[4-(4-Fluoro-benzylidene)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;~~

~~1-{2-[4-(4-Bromo-benzylidene)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;~~

1-{2-[4-(3-Methyl-benzyl)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;

1-{2-[4-(2-Methyl-benzyl)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;

1-{2-[4-(4-Fluoro-benzyl)-piperidin-1-yl]-ethyl}-3-(2-methyl-quinolin-4-yl)-urea;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidine-4-carboxylic acid benzyl-phenyl-amide;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-piperidine-4-carboxylic acid (2-chloro-phenyl)-methyl-amide;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-methyl-amide;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid methyl-phenethyl-amide;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid benzyl-ethyl-amide;

1-{2-[3-(2-Methyl-quinolin-4-yl)-ureido]-ethyl}-4-phenyl-piperidine-4-carboxylic acid dimethylamide;

4-Benzyl-1-{2-[3-(2-methyl-quinolin-4-yl)-ureido]-ethyl}-piperidine-4-carboxylic acid benzyl-ethyl-amide;

1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methylamino-pyridin-4-yl)-urea; and

1-[2-(4-Benzyl-piperidin-1-yl)-ethyl]-3-(2-methylamino-pyridin-4-yl)-urea,

or a pharmaceutically acceptable salt of said compound.

23-29. (Cancelled).

30. (New) The compound according to claim 1 being 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea, or a pharmaceutically acceptable salt thereof.